Table 1.
Study | Strain | Treatment | Number | Duration (weeks) |
---|---|---|---|---|
Cardiac delivery | SHR | AAV9-Luc | 2 | 3 |
Toxicology | SHR | Untreated | 3 | 3 |
SHR | AAV9-Luc | 3 | 3 | |
SHR | AAV9-BNP | 3 | 3 | |
Pharmacokinetics/dynamics | SHR | Untreated | 8 | 40 |
SHR | AAV9-BNP | 8 | 40 | |
Non-cardiac delivery | SHR | Untreated | 5 | 8 |
SHR | AAV2-BNP | 5 | 8 | |
SHR | AAV9-BNP | 3 | 8 | |
Normotensive rat study | Wistar | AAV9-GFP | 6 | 4 |
Wistar | AAV9-BNP | 6 | 4 |
SHR, spontaneously hypertensive rats; Luc, luciferase; GFP, green fluorescent protein.